Stemline Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. ELZONRISď (tagraxofusp), a targeted therapy directed to CD123, is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years and older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN). In Europe, a marketing authorization application (MAA) is under review by the European Medicines Agency (EMA). ELZONRIS is also being evaluated in clinical trials in additional indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF) and acute myeloid leukemia (AML). Additional pipeline candidates include: felezonexor (SL-801) (XPO1 inhibitor; Phase 1 in advanced solid tumor patients ongoing), SL-1001 (novel RET kinase inhibitor, IND-enabling studies ongoing), SL-701 (immunotherapeutic; Phase 2 in glioblastoma patients completed), and SL-901 (novel kinase inhibitor; prior abbreviated European Phase 1, IND-enabling studies ongoing). Source
No articles found.
Headquartered in Scottsdale, Arizona, The Joint Chiropractic is revolutionizing ac...
Headquartered in Scottsdale, Arizona, The Joint...
MintHealth is a global, decentralized health platform that aligns healthcare stake...
MintHealth is a global, decentralized health pl...
PDS Biotechnology has a growing pipeline of clinical-stage immunotherapies to trea...
PDS Biotechnology has a growing pipeline of cli...
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and ...
Catalyst Pharmaceuticals is a biopharmaceutical...
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing ...
Clearside Biomedical, Inc. is a biopharmaceutic...
Proteostasis Therapeutics, Inc. is an innovative biopharmaceutical company committ...
Proteostasis Therapeutics, Inc. is an innovativ...
Morphic Therapeutic is leading the development of a new generation of oral integri...
Morphic Therapeutic is leading the development ...
Join the National Investor Network and get the latest information with your interests in mind.